ITEMS IN AFP WITH KEYWORD:
Stroke and TIA
Mar 1, 2021 Issue
Antiplatelet Agents for Preventing Early Recurrence of Ischemic Stroke or TIA [Medicine by the Numbers]
After atherothrombotic ischemic stroke or transient ischemic attack, adding clopidogrel to aspirin reduced recurrent strokes but increased major hemorrhages.
For patients with mild to moderate acute nonembolic ischemic stroke, treatment with ticagrelor plus aspirin for 30 days resulted in fewer subsequent strokes but similar overall disability and an increase in severe bleeding compared with aspirin alone.
Icosapent ethyl is safe, well tolerated and effective in preventing ischemic events including stroke and heart attack.
Learn more about the effect of aspirin therapy given within 48 hours of acute ischemic stroke in reducing the risk of death, dependence, or recurrent stroke, and the chance of complete recovery.
PPAR gamma agonists are probably effective in preventing recurrent stroke in people with previous stroke or TIA.
A lower LDL target slightly reduced the likelihood of a broad composite outcome (number needed to treat [NNT] = 43 over 3.5 years), largely by reducing nonfatal strokes (NNT = 77; statistical significance not reported).
Based on a recent randomized controlled trial followed by a systematic review, the BMJ and MAGIC group concluded that dual antiplatelet therapy use for a limited period after mild stroke is beneficial.
Combined treatment with clopidogrel and aspirin, started within 24 hours of the first event, will decrease the likelihood of a recurrent stroke in an additional 2% of patients compared with aspirin alone, with a slight increase in the risk of extra-cranial bleeding.
Aug 15, 2019 Issue
Asthma, Back and Neck Pain, Pain During Labor, TIA, CBT for Anxiety [AFP Clinical Answers]
Key clinical questions and their evidence-based answers directly from the journal’s content, written by and for family physicians.
Direct oral anticoagulants are as likely as warfarin to prevent all strokes and systemic embolic events in patients with atrial fibrillation and CKD stage 3. They do not increase the risk of major bleeding events. The evidence remains insufficient to make recommendations for the use of direct oral a...